The estimated Net Worth of Geoffrey Hulme is at least $136 Thousand dollars as of 15 February 2019. Geoffrey Hulme owns over 7,000 units of Innoviva Inc stock worth over $135,800 and over the last 6 years Geoffrey sold INVA stock worth over $0.
Geoffrey has made over 1 trades of the Innoviva Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Geoffrey bought 7,000 units of INVA stock worth $103,600 on 15 February 2019.
The largest trade Geoffrey's ever made was buying 7,000 units of Innoviva Inc stock on 15 February 2019 worth over $103,600. On average, Geoffrey trades about 1,400 units every 0 days since 2019. As of 15 February 2019 Geoffrey still owns at least 7,000 units of Innoviva Inc stock.
You can see the complete history of Geoffrey Hulme stock trades at the bottom of the page.
Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital..., and Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
Innoviva Inc executives and other stock owners filed with the SEC include: